The pharmacology of CGS 25462: a potent, orally bioavailable, long-acting inhibitor of neutral endopeptidase 24.11.
Trapani
A J
AJ
Research Department, Ciba-Geigy Corporation, Summit, NJ 07901.
De Lombaert
S
S
Erion
M D
MD
Ghai
R D
RD
Peppard
J V
JV
Lappe
R W
RW
Worcel
M
M
D000284:Administration, Oral; D000595:Amino Acid Sequence; D000818:Animals; D009320:Atrial Natriuretic Factor / Q000097:blood; D001682:Biological Availability; D001713:Biphenyl Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology; D008969:Molecular Sequence Data; D015260:Neprilysin / Q000037:antagonists & inhibitors*; D009842:Oligopeptides / Q000737:chemistry; D063065:Organophosphonates / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D011355:Prodrugs / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology; D051381:Rats; D013379:Substrate Specificity
D001713:Biphenyl Compounds; D009842:Oligopeptides; D063065:Organophosphonates; D011355:Prodrugs; C086165:CGS 25462; D009320:Atrial Natriuretic Factor; D015260:Neprilysin